2023³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö : 2023-04-06
±³À°ÀÏÀÚ : 2023-04-06
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ, ºÎ»ê
±³À°ÁÖÁ¦ : 2023³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ³»ºÐºñÇÐȸ
¿¬¶ôó : 02-2038-0072
À̸ÞÀÏ : endo@endocrinology.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í Àü¹®ÀÇ/ÀüÀÓÀÇ/±³¼ö/°³¿øÀÇ/±âÃÊÀÇÇÐÀÚ : 10¸¸¿ø (ºñȸ¿ø 15¸¸¿ø) Àü°øÀÇ/´ëÇпø»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/°£È£»ç/¿µ¾ç»ç/ÀÇ·á±â»ç/±âŸ : 5¸¸¿ø (ºñȸ¿ø 7¸¸¿ø) *¸¸ 65¼¼ ÀÌ»ó Æò»ýȸ¿ø : ¹«·á **Àü°øÀÇ, ´ëÇпø»ýÀ» Á¦¿ÜÇÑ Çлý : ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-06 Room 1 16:30~17:00 ±¹¹Îº¸°Çȯ°æ±âÃÊÁ¶»ç ÀÚ·á¿¡ ³ªÅ¸³ ¿ì¸® ±¹¹ÎÀÇ È¯°æÀ¯Çع°Áú ³ëÃâ ÇöȲ ±è¿ÁÁø(±¹¸³È¯°æ°úÇпø)
±³À°½Ã°£ 04-06 Room 1 17:00~17:30 »ýÈ°ÈÇÐÁ¦Ç° ³» EDCÀÇ È¥ÇÕ Á¶ÇÕ È®Àΰú µ¶¼ºÆò°¡ Áö°æÈñ(¿ëÀδëÇб³ »ê¾÷º¸°Çȯ°æÇаú)
±³À°½Ã°£ 04-06 Room 1 17:30~18:00 ºòµ¥ÀÌÅ͸¦ ÀÌ¿ëÇÑ EDCÀÇ °Ç° ¿µÇâ Æò°¡ ÀÌȯÈñ(ºÎ»ê´ëÇб³ Á¤º¸ÀÇ»ý¸í°øÇдëÇÐ)
±³À°½Ã°£ 04-06 Room 2 16:30~17:00 Histopathologic basis of clinical diversity in patients with primary aldosteronism ¾Èâȣ(ºÐ´ç¼¿ï´ëº´¿ø³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-06 Room 2 17:00~17:30 CT-derived bone density predicts surgical outcomes in primary aldosteronism À̽ÂÇö(¿øÁÖÀÇ´ë³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-06 Room 2 17:30~18:00 Body composition and metabolic features in patients with adrenal incidentaloma and referent subjects. Á¤°æ¿¬(³ë¿øÀ»Áö´ëº´¿ø³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-06 Room 3 16:30~17:00 Resveratrol À¯µµÃ¼ÀÇ influenza A ¹ÙÀÌ·¯½º ÀúÇØ È°¼º ÃÖÃáȯ(°æ±âµµ°æÁ¦°úÇÐÁøÈï¿ø ¹ÙÀÌ¿À¼¾ÅÍ)
±³À°½Ã°£ 04-06 Room 3 17:00~17:30 õ¿¬¹° À¯·¡ È¿´É¼ººÐÀ» ÀÌ¿ëÇÑ ¿©¼º °»³â±â ¾È¸éÈ«Á¶ Ä¡·áÁ¦ °³¹ß Á¤¼±¿ë(¾ÆÁÖ´ë »ý¸í°úÇаú)
±³À°½Ã°£ 04-06 Room 3 17:30~18:00 Äí½ÌÁõÈıº Ä¡·á õ¿¬¹° ÀǾàÇ° °³¹ß: ¹ÌÅäÄܵ帮¾Æ ´ë»ç Á¶Àý Áß½ÉÀ¸·Î °í¿µÈÆ(Çѱ¹ÇÑÀÇÇבּ¸¿ø ÇÑÀDZâ¼úÀÀ¿ë¼¾ÅÍ)
ÈÞ½Ä 04-06 18:00~19:00 ÈÞ½Ä ()
±³À°½Ã°£ 04-06 Room 1 19:00~19:25 ±Ù°ÅÁß½ÉÀÇ ÀÇÇÐÀ¸·Î º» ÃֽŠ´ç´¢º´ °ü¸® Å°¿öµå ³ëÁ¤Çö(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04-06 Room 1 19:25~19:50 º¯ÈÇÏ´Â ´ç´¢ Ä¡·á Æ®·»µå ¼Ó DPP4 ¾ïÁ¦Á¦ÀÇ ¿ªÇÒ ±èÇý¼ø(°è¸íÀÇ´ë)
Åä·Ð 04-06 Room 1 19:50~20:00 Åä·Ð ()
±³À°½Ã°£ 04-06 Room 2 19:00~19:25 SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes? ¹ÚÁ¤È¯(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-06 Room 2 19:25~19:50 Reno-protection from Sglt-2 inhibitors across the spectrum of risk ±Ç¹ÎÁ¤(ºÎ»ê¹éº´¿ø)
Åä·Ð 04-06 Room 2 19:50~20:00 ()